Charles River Laboratories International (CRL) Asset Writedowns and Impairment (2022 - 2025)

Charles River Laboratories International's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment fell 94.43% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $6.1 million (down 82.79% YoY), while the FY2025 annual figure was $6.1 million, down 88.3% from the prior year.
• Asset Writedowns and Impairment for Q4 2025 stood at $1.5 million, up from -$26.6 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $27.0 million in Q4 2024, with the low at -$26.6 million in Q3 2025.
• The 4-year median for Asset Writedowns and Impairment is $4.8 million (2024), against an average of $4.1 million.
• Peak annual rise in Asset Writedowns and Impairment reached 1299.85% in 2025, while the deepest fall reached 651.86% in 2025.
• Charles River Laboratories International's Asset Writedowns and Impairment stood at $6.0 million in 2022, then plunged by 179.36% to -$4.7 million in 2023, then jumped by 669.62% to $27.0 million in 2024, then plunged by 94.43% to $1.5 million in 2025.
• Business Quant data shows CRL's Asset Writedowns and Impairment at $1.5 million in Q4 2025, -$26.6 million in Q3 2025, and $24.4 million in Q2 2025.